Search Results for: GE Healthcare Advances the Delivery
Articles
INTRADERMAL DELIVERY - Advances in Intradermal Drug Delivery October 16, 2013
Zach Marks, MS, RPh, believes efficiency of vaccine use will be critical as the world population continues to grow and vaccine prices continue to rise, and ID administration can help reduce dose cost while potentially improving immunogenicity in traditional and hard-to-treat populations.
ADVANCED DELIVERY DEVICES - The Reconstitution Revolution October 15, 2013
Alan Shortall believes with dual-chamber syringes and other emerging device technologies now addressing key market requirements for intuitive reconstitution and injection, the pharmaceutical market for therapies suitable for reconstitution and mixing at the point of delivery is poised for significant rates of growth.
EXECUTIVE INTERVIEW - Capsugel DFS: Integrating Technology for Innovative Finished Dosage Forms October 2, 2013
Drug Development Executive: Amit Patel, President of Capsugel’s Dosage Form Solutions business unit, speaks about the formulation challenges facing the industry and the increasing pressure on companies to remain competitive in today’s dynamic marketplace.
ADVANCED DELIVERY DEVICES - IntelliCap: An Intelligent, Electronic Capsule for Oral Drug Delivery & Development March 31, 2013
Jeff Shimizu and Christoph Wanke, PhD, indicate electronic smart pills represent an emerging area with great potential for growth. Already established in the diagnostic area, the next move is into monitoring and drug delivery.
INNOVATION AWARDS - Drug Delivery Award Winners Move Innovation Needle; Formulation Takes Center Stage March 31, 2013
Marc Dresner presents the three companies that were honored by their industry peers with prestigious awards for breakthrough drug delivery innovation at the Institute for International Research’s 17th annual Drug Delivery Partnerships conference.
THERAPEUTIC FOCUS: Sufentanil NanoTab Technology: Revolutionizing Patient-Controlled Analgesia March 31, 2013
Pamela P. Palmer, MD, PhD; examines how AcelRx’s system can deliver the benefits of PCA in terms of patient pain relief and satisfaction while reducing both drug and device safety risks as well as the overall complexity of pain management, thus reducing both drug and device safety risks as well as the overall complexity of pain management, thus reducing the cost burden on the healthcare system.
GSK Successfully Uses Capsugel's Licaps June 11, 2012
Capsugel recently announced that its Licaps liquid-filled hard capsules have been successfully used by major healthcare company, GlaxoSmithKline (GSK), for...Encap Drug Delivery & Lena Nanoceutics to Develop Nano-Capsule Technology October 27, 2011
Encap Drug Delivery and Lena Nanoceutics recently announced a collaboration agreement to develop a new drug delivery technology (Nano-Capsules) that...Unilife Develops Multiple-Chamber Prefilled Syringes August 25, 2011
Unilife Corporation recently announced the development and patenting of the Unifill EZMix multiple-chamber ready-to-fill (prefilled) syringes. Unifill EZMix syringes have...Lisata Therapeutics & Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial April 23, 2024
Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co., Ltd. recently announced the first patient has been treated in Qilu’s Phase 2...EXECUTIVE INTERVIEW - Samsung Biologics: Exploring The Evolving Biopharma Landscape January 26, 2024
Kevin Sharp, Senior VP & Head of Sales for Samsung Biologics, discusses the evolving biopharma space, exploring current challenges, and the demand for sustainable solutions.
Absci Announces Collaboration With AstraZeneca to Advance AI-Driven Oncology Candidate December 4, 2023
Absci Corporation recently announced a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. This collaboration combines...SPECIAL FEATURE - Injection Devices: Designing in Sustainability, Usability & Digitization for Patient Compliance September 5, 2023
Contributor Cindy H. Dubin, in this exclusive annual feature, highlights how leading device and drug companies are working to address the challenges of usability, sustainability, and technology to increase patient compliance.
EXECUTIVE INTERVIEW - ICON: Transforming Clinical Trials in a Rapidly Shifting Landscape April 3, 2023
Ute Berger, MD, President, Development & Commercialization Solutions at ICON plc, discusses how with the acquisition of PRA in 2021, it has enhanced its value proposition and how it is transforming clinical trials in a rapidly shifting landscape.
SPECIAL FEATURE - Solubility & Bioavailability: Difficult Beasts to Tame March 1, 2023
Contributor Cindy H. Dubin highlights the services many of these outsourced providers offer to enhance solubility and bioavailability and get their clients’ projects to market faster and cost effectively – while maintaining critical quality attributes.
ROUNDTABLE DISCUSSION - Which Trends Will Have the Most Impact on Drug Development in 2023? January 16, 2023
Contributor Cindy H. Dubin posed this question to life science leaders during a recent roundtable discussion, and one common theme is the focus on sustainability in pharmaceutical development.
NANOPARTICLE ENGINEERING - Lighting the Way to a Patient-Centric Future October 3, 2022
Christopher Worrall, PhD, discusses how nanoparticle engineering technologies could help improve compliance and patient outcomes, for both small-molecule and biological drugs, and how nanotechnology can help facilitate a shift toward more patient-centric medicine.
SYNTHETIC ANTI-INFECTIVES - Synthetic Polymers Offer a New Class of Anti-Infectives June 1, 2022
James Graham believes synthetic anti-infectives offer a potential solution to the obstacles encountered by naturally derived antibiotics in the constant arms race against antimicrobial resistance.
SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies March 1, 2022
Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.
Moderna Announces First Participant Dosed in Phase 1 Study of its Epstein-Bar Virus Vaccine January 5, 2022
Moderna, Inc. recently announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus...
